Interpace Diagnostics Group, Inc. is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Our tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.
We work to improve patient care through personalized medicine driven by molecular diagnostic tests that are supported by rigorous science. Via our unique molecular diagnostic tests, healthcare providers will be able to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. We currently have five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.View Diagnostic Products
All of our testing services are performed in our clinical reference laboratories located in Pittsburgh, Pennsylvania and New Haven, Connecticut, which have Clinical Laboratory Improvement Amendment (CLIA) certification and have been accredited by the College of American Pathologists (CAP).View Labs